Patents by Inventor Katherine CYGNAR
Katherine CYGNAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240052051Abstract: Provided, in part, are an anti-human transferrin receptor antigen-binding proteins and fusion proteins comprising an anti-human transferrin receptor antigen-binding proteins (e.g., in scFv, Fab or antibody format) which may be fused to a payload for delivery of the payload to a targeted tissue (e.g., past the blood-brain barrier and to the brain). Payloads include, for example, alpha-glucosidase (GAA) polypeptide. Methods for treating various diseases with such molecules, e.g., glycogen storage diseases, such as Pompe Disease, with the fusions are provided.Type: ApplicationFiled: July 28, 2023Publication date: February 15, 2024Inventors: Nicole Keating, Pascaline Aimé-Wilson, John Dugan, Min Gao, Robert Babb, Maria Praggastis, Katherine Cygnar, Bojie Zhang
-
Publication number: 20230345919Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.Type: ApplicationFiled: May 19, 2023Publication date: November 2, 2023Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel H. Martin
-
Publication number: 20230338477Abstract: Nucleic acid constructs and compositions that allow insertion of a multidomain therapeutic protein (e.g., GAA fusion protein) coding sequence into a target genomic locus such as an endogenous ALB locus and/or expression of the multidomain therapeutic protein (e.g., GAA fusion protein) coding sequence are also provided. The nucleic acid constructs and compositions can be used in methods of integration of a multidomain therapeutic protein (e.g., GAA fusion protein) nucleic acid into a target genomic locus, methods of expression of a multidomain therapeutic protein (e.g., GAA fusion protein) in a cell, methods of reducing glycogen accumulation, methods of treating Pompe disease or GAA deficiency in a subject, and method of preventing or reducing the onset of a sign or symptom of Pompe disease in a subject, including neonatal cells and subjects.Type: ApplicationFiled: February 2, 2023Publication date: October 26, 2023Inventors: Andrew Baik, Maria Praggastis, Katherine Cygnar, Leah Sabin, Poulami Samai, Evangelos Pefanis, Philip Calafati, Nicole Keating, Pascaline Aimé-Wilson, John Dugan, Min Gao, Robert Babb, Anthony Forget
-
Publication number: 20230220100Abstract: Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases, are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein, e.g., anti-TfRCscfv:GAA, that crosses the blood brain barrier (BBB) are provided.Type: ApplicationFiled: January 10, 2023Publication date: July 13, 2023Inventors: Katherine Cygnar, Maria Praggastis
-
Patent number: 11696572Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.Type: GrantFiled: June 27, 2018Date of Patent: July 11, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel H. Martin
-
Publication number: 20230149563Abstract: Nucleic acid constructs and compositions that allow insertion of a FIX coding sequence into a target genomic locus such as an endogenous ALB locus and/or expression of the FIX coding sequence are provided. The nucleic acid constructs and compositions can be used in methods of introducing a F9 nucleic acid into a cell, methods of integration of a F9 nucleic acid into a target genomic locus, methods of expression of FIX in a cell, and in methods of treating hemophilia B or FIX deficiency in a subject.Type: ApplicationFiled: October 27, 2022Publication date: May 18, 2023Inventors: Leah Sabin, Christos Kyratsous, Evangelos Pefanis, Sven Moller-Tank, Joseph Katakowski, Andrew Baik, Katherine Cygnar, Poulami Samai, Philip Calafati
-
Publication number: 20220267477Abstract: The present invention provides multispecific antigen-binding molecules and methods of making or selecting same. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.Type: ApplicationFiled: May 4, 2022Publication date: August 25, 2022Inventors: Katherine Cygnar, Frank Delfino
-
Publication number: 20220195011Abstract: Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multidomain therapeutic proteins are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.Type: ApplicationFiled: November 17, 2021Publication date: June 23, 2022Inventors: Andrew Baik, Katherine Cygnar, Christopher Schoenherr, Christos Kyratsous, Cheng Wang
-
Patent number: 11352446Abstract: The present invention provides multispecific antigen-binding molecules and methods of making or selecting same. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.Type: GrantFiled: April 28, 2017Date of Patent: June 7, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Katherine Cygnar, Frank Delfino
-
Publication number: 20220008548Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.Type: ApplicationFiled: September 23, 2021Publication date: January 13, 2022Inventors: Julian Andreev, Nithya Thambi, Frank Delfino, Joel Martin, Gavin Thurston, Katherine Cygnar, Nicholas Papadopoulos
-
Patent number: 11208458Abstract: Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multidomain therapeutic proteins are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.Type: GrantFiled: June 6, 2018Date of Patent: December 28, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Andrew Baik, Katherine Cygnar, Christopher Schoenherr, Christos Kyratsous, Cheng Wang
-
Patent number: 11191844Abstract: The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.Type: GrantFiled: July 6, 2016Date of Patent: December 7, 2021Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Julian Andreev, Nithya Thambi, Frank Delfino, Joel Martin, Gavin Thurston, Katherine Cygnar, Nicholas Papadopoulos
-
Patent number: 11129903Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.Type: GrantFiled: July 6, 2016Date of Patent: September 28, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Julian Andreev, Nithya Thambi, Frank Delfino, Joel Martin, Gavin Thurston, Katherine Cygnar, Nicholas Papadopoulos
-
Publication number: 20210079109Abstract: Antibodies, portions, and fusion proteins thereof to CD63 are provided. Also provided are nucleic acid sequences encoding same. Also provided are compositions comprising and methods of using same, e.g., for treating a patient in need thereof.Type: ApplicationFiled: May 17, 2019Publication date: March 18, 2021Inventors: Katherine CYGNAR, Andrew BAIK, Christopher SCHOENHERR, Andrew J. MURPHY
-
Publication number: 20200399623Abstract: Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein that crosses the blood brain barrier (BBB) are provided.Type: ApplicationFiled: February 7, 2019Publication date: December 24, 2020Inventors: Andrew Baik, Katherine Cygnar, Maria Praggastis
-
Publication number: 20200154684Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.Type: ApplicationFiled: June 27, 2018Publication date: May 21, 2020Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel Martin
-
Publication number: 20200095338Abstract: The present invention provides multispecific antigen-binding molecules and methods of making or selecting same. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.Type: ApplicationFiled: April 28, 2017Publication date: March 26, 2020Inventors: Katherine Cygnar, Frank Delfino
-
Publication number: 20190112588Abstract: Compositions and methods for treating lysosomal storage diseases are disclosed. Biotherapeutic complexes containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The biotherapeutic complexes are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.Type: ApplicationFiled: December 8, 2016Publication date: April 18, 2019Inventors: Andrew BAIK, Katherine CYGNAR
-
Publication number: 20190000984Abstract: The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.Type: ApplicationFiled: July 6, 2016Publication date: January 3, 2019Inventors: Julian Andreev, Nithya Thambi, Frank Delfino, Joel Martin, Gavin Thurston, Katherine Cygnar, Nicholas Papadopoulos
-
Publication number: 20180355017Abstract: Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multidomain therapeutic proteins are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.Type: ApplicationFiled: June 6, 2018Publication date: December 13, 2018Inventors: Andrew Baik, Katherine Cygnar, Christopher Schoenherr, Christos Kyratsous, Cheng Wang